louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04860037: Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic Patients
Official title: Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic Patients : What About Their Consequences ?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acromegaly
Keywords: Endocrinology
Acromegaly
Discrepancy
Complications
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2021-04-26
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult acromegalic patient followed up in the Occitanie region (independent endocrinologist ou working in hospital of Montpellier, Nimes or Béziers)

Brief summary: The diagnosis and the follow-up of acromegalic patients are based on the mesurement of Growth hormone (GH) and IGF1 rates. However, the literature described some cases of patient for whom the investigators observed a discrepancy between GH and IGF1 rates. Since the acromegaly is a rare disease and this phenomenon concerns about 30% of these patients, there is a lack of investigations about consequences that this discordance may induces. In this study, the investigators aimed at assessing if patients with discordance between GH and IGF1 rates present a different risk of recurrence and complications related to acromegaly, from patients with concordant results.


Eligibility criteria: Inclusion criteria:

* Acromegaly followed up in one of the center (Montpellier, Nimes or Béziers hospital, independent endocrinologist) between 2010 and 2021
* Age over 18 years old
* Measurement of GH and IGF1 rates at the last visit control available

Exclusion criteria:

* Lost to follow-up
* Status about complications related to acromegaly unknown

Primary outcomes:
measure: Occurrence of complications and/or recidivism related to acromegaly
timeFrame: day 1
Secondary outcomes:
measure: Disease's specificity
timeFrame: day 1
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Isabelle RAINGEARD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03485937: Impact of Videos on Patient Anxiety and Satisfaction
Official title: Impact of Pre-Operative Videos on Mohs Surgery Patient Anxiety and Satisfaction
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Mohs Surgery
Keywords: anxiety
patient satisfaction
video education
skin cancer
linear closure on the face
Lead sponsor: Case Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2018-04-03
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this research is to look at how educational videos might affect patient satisfaction and anxiety before Mohs surgery day. Patients will be randomized to either: 1) a group that receives educational videos before the visit in addition to standard-of-care written and verbal instructions OR 2) a group that receives only standard-of-care written and verbal instructions.

Detailed description: The primary objective of this study is to determine if pre-operative videos describing the patient's forthcoming day in the Mohs clinic decrease pre-operative patient anxiety and increase postoperative patient satisfaction, when added to standard of care written and verbal instruction.

Design/Study Type This study will be a randomized control trial in which patients will be randomized to either the intervention (pre-operative Mohs Surgery video viewing) or control (standard of care) group in order to understand the impact of the video on patient anxiety and satisfaction. Patients will be randomized using an Accelerated Biased Coin Design in the statistical program R.

Eligibility criteria: Inclusion Criteria:

* Patients who are at the University Hospitals Cleveland Medical Center Mohs Clinic to undergo a linear closure on the face.
* Fluent English speakers

Exclusion Criteria:

* Non-fluent English speakers

Primary outcomes:
measure: Difference in mean Likert scale rating of subject satisfaction score
timeFrame: Up to 8 weeks after visit
measure: Difference in mean Likert scale rating of subject anxiety score
timeFrame: Up to 8 weeks after visit
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University Hospitals, Case Comprehensive Cancer Center
name: Jeremy S. Bordeaux, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01981837: Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
Official title: A Phase 2, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Exploratory Clinical Activity of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: TTR-mediated Amyloidosis
Keywords: RNAi therapeutic
Lead sponsor: Alnylam Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2013-11-13
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the pharmacokinetics, pharmacodynamics and exploratory clinical activity of ALN-TTRSC (revusiran) in Patients with Transthyretin (TTR) Cardiac Amyloidosis.


Eligibility criteria: Inclusion Criteria:

* TTR cardiac amyloidosis;
* Women of child-bearing potential (WOCBP) must have a negative pregnancy test, cannot be breast feeding, and must be willing to use 2 highly effective methods of contraception;
* Male subjects agree to use appropriate contraception;
* Adequate blood counts, liver, renal and heart function;
* Adequate Karnofsky performance status;
* Adequate New York Heart Association (NYHA) Classification Score;
* Clinically stable on heart medications;
* Adequate 6-minute walk test;
* Willing to give written informed consent and are willing to comply with the study requirements.

Exclusion Criteria:

* Known human immunodeficiency virus (HIV) positive status or known or suspected systemic bacterial, viral, parasitic, or fungal infection;
* Subjects with a history of multiple drug allergies or intolerance to SC injection;
* Received an investigational agent other than tafamidis, diflunisal, doxycycline or tauroursodeoxycholic acid, or an investigational device within 30 days prior to first dose of study;
* Uncontrolled hypertension, ischemic heart disease or cardiac arrhythmia;
* Untreated hypo- or hyperthyroidism;
* Prior major organ transplant;
* Considered unfit for the study by the Principal Investigator.

Primary outcomes:
measure: The proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs) and study drug discontinuation.
timeFrame: Up to 63 days
Secondary outcomes:
measure: Pharmacokinetics (PK) of ALN-TTRSC (revusiran) (Cmax, tmax, t1/2, AUC, CL, Vss, Vz)
timeFrame: Up to 90 days
measure: Effect of ALN-TTRSC (revusiran) on transthyretin (TTR) (Determination of % Lowering of TTR to pretreatment/Baseline Levels)
timeFrame: Up to 90 days
Other outcomes:
Locations:
city: Boston
country: United States
facility: Clinical Trial Site
state: Massachusetts
city: New York
country: United States
facility: Clinical Trial Site
state: New York
city: Cleveland
country: United States
facility: Clinical Trial Site
state: Ohio
city: London
country: United Kingdom
facility: Clinical Trial Site
Study officials:
affiliation: Alnylam Pharmaceuticals
name: Jared Gollob, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00298337: Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Atopic Dermatitis
Food Hypersensitivity
Allergic Rhinitis, Seasonal
Allergic Conjunctivitis
Asthma
Lead sponsor: University of Helsinki
Sponsor class: OTHER
First posted: 2006-03-02
Sex: ALL
Minimum age (years): 37
Maximum age (years): 42
Standard ages: CHILD
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of the study is to find out if allergic diseases can be prevented buy giving probiotic bacteria to pregnant mothers and their newborn infants


Eligibility criteria: Inclusion Criteria:

* mother or father fo child with doctor diagnoses allergic disease

Exclusion Criteria:

* prematurity, major malformations

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Helsinki University Central Hospital, Skin and Allergy Hospital
state: PO box 160
Study officials:
affiliation: Helsinki University Central Hospital, Hospital for Children and Adults, PO Box 281, 00029 HUS, Finland
name: Erkki Savilahti, Professor
role: STUDY_CHAIR
References:
citation: Korpela K, Kallio S, Salonen A, Hero M, Kukkonen AK, Miettinen PJ, Savilahti E, Kohva E, Kariola L, Suutela M, Tarkkanen A, de Vos WM, Raivio T, Kuitunen M. Gut microbiota develop towards an adult profile in a sex-specific manner during puberty. Sci Rep. 2021 Dec 2;11(1):23297. doi: 10.1038/s41598-021-02375-z.
citation: Kallio S, Kukkonen AK, Savilahti E, Kuitunen M. Perinatal probiotic intervention prevented allergic disease in a Caesarean-delivered subgroup at 13-year follow-up. Clin Exp Allergy. 2019 Apr;49(4):506-515. doi: 10.1111/cea.13321. Epub 2018 Dec 18.
citation: Korpela K, Salonen A, Vepsalainen O, Suomalainen M, Kolmeder C, Varjosalo M, Miettinen S, Kukkonen K, Savilahti E, Kuitunen M, de Vos WM. Probiotic supplementation restores normal microbiota composition and function in antibiotic-treated and in caesarean-born infants. Microbiome. 2018 Oct 16;6(1):182. doi: 10.1186/s40168-018-0567-4.
citation: Savilahti EM, Kukkonen AK, Haahtela T, Tuure T, Kuitunen M, Savilahti E. Intestinal defensin secretion in infancy is associated with the emergence of sensitization and atopic dermatitis. Clin Exp Allergy. 2012 Mar;42(3):405-11. doi: 10.1111/j.1365-2222.2011.03904.x. Epub 2011 Nov 16.
citation: Kukkonen AK, Savilahti EM, Haahtela T, Savilahti E, Kuitunen M. Ovalbumin-specific immunoglobulins A and G levels at age 2 years are associated with the occurrence of atopic disorders. Clin Exp Allergy. 2011 Oct;41(10):1414-21. doi: 10.1111/j.1365-2222.2011.03821.x. Epub 2011 Jul 19.
citation: Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, Kuitunen M. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics. 2008 Jul;122(1):8-12. doi: 10.1542/peds.2007-1192.
Clinical trial NCT02062437: Clinical and Radiological Results of Total Hip Arthroplasty Using a Ceramic Friction Pair
Official title: Multicentric Observational Study Evaluating Clinical and Radiological Results of a Total Hip Arthroplasty Using a Ceramic Friction Pair
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hip Replacement
Primary, Secondary or Post-traumatic Osteoarthrosis
Femur Head Necrosis
Congenital Dislocations
Keywords: Arthroplasty
Hip Replacement
Ceramic
Acetabular cup
Femoral stem
Lead sponsor: Stryker Trauma and Extremities
Sponsor class: INDUSTRY
First posted: 2014-02-13
Enrollment: 132
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Cohort of European patients with a primary total hip replacement using a ceramic friction pair including Meije Duo® stem associated with a Dynacup® cup.

Brief summary: The aim of this study is to assess safety and general performance of total hip arthroplasty, composed of a Meije Duo® femoral stem associated with a Dynacup® cup, and using the friction pair Biolox® Delta Ceramic.


Eligibility criteria: Inclusion Criteria:

* Male or female patient implanted with a primary total hip replacement using a ceramic friction pair including Meije Duo® stem associated with a Dynacup® cup.
* Aged of more than 18 years at the time of the surgery.
* Patient with a follow-up of at least 2 years after surgery based on a consecutive and exhaustive series of patients operated within the inclusion period.
* Able to understand information to participate to the study.

Exclusion Criteria:

* Patient having a tumoral pathology.
* Patient having expressed opposition to the study participation.

Primary outcomes:
measure: Number of Participants With Adverse Events
timeFrame: 2-year follow-up visit
Secondary outcomes:
measure: General Performance: Mobility
timeFrame: Baseline
measure: General Performance: Mobility
timeFrame: 2-year Follow-up visit
Other outcomes:
measure: General Performance: Objective Clinical Score (PMA)
timeFrame: Baseline
measure: General Performance: Objective Clinical Score (PMA)
timeFrame: 2-year follow-up visit
measure: General Performance: Radiological Assessment.
timeFrame: 2-year Follow-up visit
Locations:
Study officials:
affiliation: Hôpital Universitaire Raymond Poincaré, Garches - France
name: Philippe Piriou, MD, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02289937: Effect of a Lateral Nerve of the Thigh Block on Postoperative Pain After Total Hip Replacement Surgery
Official title: Effect of a Lateral Nerve of the Thigh Block on Postoperative Pain After Total Hip Replacement Surgery: a Clinical Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain, Postoperative
Anesthesia, Conduction
Arthroplasty, Replacement, Hip
Keywords: Postoperative pain
regional anaesthesia
total hip replacement
nervus cutaneous femoral lateralis
Lead sponsor: Naestved Hospital
Sponsor class: OTHER
First posted: 2014-11-13
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to evaluate the analgesic efficacy of the nervus cutaneous femoral lateralis (NCFL) blockade on postoperative pain after total hip replacement surgery. The NCFL-block is a pure sensory block. We hypothesized that the NCFL-block would reduced the postoperative pain without delaying mobilization.


Eligibility criteria: Inclusion Criteria:

* Primary total hip replacement

Exclusion Criteria:

* general anaesthesia
* Allergy to local anesthetics of the amide type
* Revision surgery
* Bilateral surgery
* Chronic pain patient
* Women in the fertile age

Primary outcomes:
measure: VAS-score 4 hours postoperative during movement
timeFrame: 4 hours postoperative
Secondary outcomes:
measure: VAS-score 0-24 hours postoperative during movement
timeFrame: 0-24 hours postoperatively
measure: VAS-score 0-24 hours postoperative at rest
timeFrame: 0-24 hours postoperatively
measure: Oxynorm consumption
timeFrame: 0-24 hours postoperative
measure: time to first oxynorm requirement
timeFrame: 0-24 hours postoperatively
measure: Mobilization
timeFrame: 0-24 hours postoperatively
measure: Mobilization
timeFrame: 0-24 hours postoperatively
measure: Length of stay
timeFrame: 0-7 days postoperative
Other outcomes:
Locations:
Study officials:
affiliation: Naestved Hospital, Department of Anaesthesiology
name: Daniel Hägi-Pedersen, M.D., Ph.D.
role: STUDY_CHAIR
References:
Clinical trial NCT02248337: Low Volume Colon Preparation for IBD
Official title: Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Inflammatory Bowel Disease
Keywords: Colon preparation; Colonoscopy; Inflammatory bowel disease
Lead sponsor: Luigi Sacco University Hospital
Sponsor class: OTHER
First posted: 2014-09-25
Enrollment: 216
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Comparison of two PEG-based bowel cleansing regimens in patients with inflammatory bowel disease.

Detailed description: Low-volume preparations are gaining attention for higher acceptability. This study compares efficacy, safety and tolerability of a 2L PEG solution plus bisacodil with a 4L PEG solution in patients with inflammatory bowel disease-related colitis.

This will be a multicenter, randomized, single-blind study. Adult outpatients with IBD colitis undergoing colonoscopy will receive either 2L PEG plus biscodil or 4L PEG. Bowel cleansing will be assessed using the Ottawa Scale and rated as adequate if \<6. Patient acceptance, satisfaction, and related symptoms will be also recorded. The study will also focus on the factors affecting quality of preparation in inflammatory bowel disease patients such as disease characteristics and administration regimen

Eligibility criteria: Inclusion Criteria:

-Adult outpatiets with IBD colitis undergoing colonoscopy

Exclusion Criteria:

* Previous colon resection, ileus, intestinal obstruction, toxic megacolon, severe heart failure (NYHA Class III or IV), acute cardiovascular disease, uncontrolled arterial hypertension (systolic pressure \>170 mmHg, diastolic pressure \>100 mmHg), severe liver cirrhosis (Child-Pugh score C) or renal failure (creatinine clearance\<30 mL/minute), ascites, phenylketonuria, and glucose-6-phosphate dehydrogenase deficiency
* Pregnant or breastfeeding women were also excluded

Primary outcomes:
measure: Efficacy
timeFrame: During endoscopy within 24 hours after preparation
Secondary outcomes:
measure: Compliance
timeFrame: during product assumption
measure: Tollerability
timeFrame: during product assumption
measure: safety
timeFrame: From drug intake to the end of colonoscopy
Other outcomes:
Locations:
city: Milano
country: Italy
facility: Luigi Sacco University Hospital
Study officials:
affiliation: AO G. Salvini Garbagnate Milanes
name: gianpiero manes, MD
role: STUDY_CHAIR
References:
citation: Manes G, Fontana P, de Nucci G, Radaelli F, Hassan C, Ardizzone S. Colon Cleansing for Colonoscopy in Patients with Ulcerative Colitis: Efficacy and Acceptability of a 2-L PEG Plus Bisacodyl Versus 4-L PEG. Inflamm Bowel Dis. 2015 Sep;21(9):2137-44. doi: 10.1097/MIB.0000000000000463.
Clinical trial NCT00693537: Exercise Training Improves Coronary Endothelial Dysfunction in Diabetes Mellitus Type 2 and Coronary Artery Disease
Official title: Long- But Not Short-term Exercise Training Improves Coronary Endothelial Dysfunction in Diabetes Mellitus Type 2 and Coronary Artery Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Type 2 Diabetes Mellitus
Coronary Artery Disease
Lead sponsor: Paracelsus Medical University
Sponsor class: OTHER
First posted: 2008-06-09
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED

Brief summary: Patients with type 2 diabetes mellitus suffer from accelerated coronary artery disease. We will assess the effects of exercise training on coronary endothelial function, vascular structure, and inflammation both in serum and skeletal muscle biopsies, as well as expression of diabetes candidate genes.


Eligibility criteria: Inclusion Criteria:

* written informed consent
* preserved left ventricular function (left ventricular ejection fraction ≥ 50%)
* a physical work capacity ≥ 50 W
* at least one significant coronary stenosis \> 50%, whereas either the left anterior descending (LAD) or circumflex artery (RCX) has to be free from disease or stenoses ≤ 25% for the assessment of intracoronary flow measurements

Exclusion Criteria:

* diseases further affecting endothelial function
* untreated hypertension (systolic blood pressure \> 160 mm Hg or a diastolic blood pressure of \> 90 mm Hg)
* cigarette smoking during the previous six months
* LDL-cholesterol \> 4.3 mmol/l
* ventricular tachyarrhythmias
* chronic obstructive pulmonary disease
* severe renal or hepatic dysfunction
* valvular heart disease
* myocardial infarction within the previous 4 weeks

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Salzburg
country: Austria
facility: University Institute of Sports Medicine, Prevention and Rehabilitation
Study officials:
References:
Clinical trial NCT05062252: Mirror Medacta Shoulder System Pivotal Trial
Official title: Multicentric, Prospective, Comparative Trial to Assess the Efficacy and Safety of an Anatomic Total Shoulder System.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Arthritis Shoulder
Post-traumatic Arthrosis of Other Joints, Upper Arm
Lead sponsor: Medacta International SA
Sponsor class: INDUSTRY
First posted: 2021-09-30
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to demonstrate safety and efficacy of the Mirror Medacta Shoulder System in total shoulder arthroplasty.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 yr
* Clinical indication for anatomic primary total shoulder replacement due to osteoarthritis and/or posttraumatic arthritis
* Willingness and ability to comply with study protocol

Exclusion Criteria:

* Medical condition or balance impairment that could lead to falls
* Prior rotator cuff surgery
* Cuff tear arthropathy/insufficient rotator cuff
* Insufficient bone quality which may affect the stability of the implant
* Neuromuscular compromise of shoulder or other disabilities affecting the maximum functional outcomes
* Weight bearing shoulder due to wheel chair, crutches, rollator at the time of operation
* Active metastatic or neoplastic disease at the shoulder joint
* Chemotherapy treatment/radiotherapy within 6 mo before surgery
* \>5 mg/day of corticosteroids, excluding inhalers, within 3 years before surgery
* Pregnancy or plan to become pregnant during study period
* Inability to understand study or a history of noncompliance with medical advice
* Alcohol or drug abuse
* Current enrollment in any clinical research study that might interfere with this study
* Metal allergies or sensitivity.
* Previous or current infection at or near the site of implantation.
* Current distant or systemic infection
* Patient, whose infomed consent form should be taken in an emergency situation
* ONLY for women of childbearing age: a positive pregnancy test (urine / blood)

Primary outcomes:
measure: Oxford Shoulder Score
timeFrame: 12 months
Secondary outcomes:
measure: Device Success Rate
timeFrame: 24 months
measure: Oxford Shoulder Score
timeFrame: 24 months
measure: Constant score
timeFrame: 24 months
measure: Subjective Shoulder Value
timeFrame: 24 months
measure: Device parameters
timeFrame: 24 months
Other outcomes:
Locations:
city: Bern
country: Switzerland
facility: Lindenhofgruppe AG - Orthopädie Sonnenhof
city: Saint Gallen
country: Switzerland
facility: Klinik für Orthopädische Chirurgie und Traumatologie des Bewegungsapparates, Kantonsspital St.Gallen
Study officials:
affiliation: Lindenhofgruppe AG (Bern)
name: Matthias A Zumstein, Prof Dr. med
role: PRINCIPAL_INVESTIGATOR
References: